CN105267228B - A kind of pharmaceutical composition is as the application in preparation treatment neuropsychiatric disorders dermatoses drug - Google Patents
A kind of pharmaceutical composition is as the application in preparation treatment neuropsychiatric disorders dermatoses drug Download PDFInfo
- Publication number
- CN105267228B CN105267228B CN201410343670.3A CN201410343670A CN105267228B CN 105267228 B CN105267228 B CN 105267228B CN 201410343670 A CN201410343670 A CN 201410343670A CN 105267228 B CN105267228 B CN 105267228B
- Authority
- CN
- China
- Prior art keywords
- kushenin
- glycyrrhizic acid
- group
- salt
- oxymatrine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
It further include glycyrrhizic acid matrine salt and glycyrrhizic acid kushenin salt the present invention relates to the derivative of kushenin (oxymatrine, matrine, Iosmatrine) and the pharmaceutically acceptable form or the two of glycyrrhizic acid or the two and containing the medicine box of these compositions.It is used to prepare the application of prevention and treatment neuropsychiatric disorders dermatoses (pruritus, lichen simplex chronicus, pruigo, prurigo nodularis, pigmentosa pruigo and lichenoid dermatitis).
Description
Technical field
The invention belongs to field of medicaments, it is related to a kind of pharmaceutical composition and is used to prepare to prevent and treat neuropsychiatric disorders
Application in skin disease.Described pharmaceutical composition contain kushenin (oxymatrine, matrine, Iosmatrine) and glycyrrhizic acid or
The pharmaceutically acceptable form of the two or the derivative of the two and the medicine box containing these compositions additionally include sweet
Oxalic acid matrine salt and glycyrrhizic acid kushenin salt.
Background technique
There are many skin skin disease type related with neuropsychiatric, and classification is not yet unified so far.It is of the present invention
Neuropsychiatric disorders dermatoses be mainly common related disease, including pruritus, lichen simplex chronicus, pruigo, knot
Section property pruigo, pigmentosa pruigo and lichenoid dermatitis.Pruritus clinically without primary cutaneous damage and based on itch
Skin disease.Itch is divided into following a few classes: skin source property itch, neuropathic itch, neurogenic itch, the heart by Twycross etc.
Source property itch, Combination itch.The receptor of itch is mediated to be located at papilla and epidermis without on the advantageous nerve ending of marrow fiber C.
These receptors can cause itch the factor with specific bond, when by cause itch the factor stimulate after, impulsion is reached ridge by a species specific fiber C
The cornu dorsale of marrow finally reaches cerebral cortex, leads to itch then by the plate layer core of the thalamus of tractus spinothalamicus.Chronic list
Pure property moss also known as neurodermatitis are the chronic inflammatory skins characterized by paroxysmal itching and skin lichenification.
Its cause of disease and pathogenesis are unclear, it is considered that related with cerebral cortex excitement and inhibition functional disturbance.Pruigo is one group
The general name of acute or chronic inflammatory dermatoses.Its major determinant is wheal sample papule, tubercle and secondary skin lesion, and surprise is itched difficulty
Bear.The cause of disease there is no final conclusion.Most scholars think related with allergy.Prurigo nodularis is the damage of excipuliform nodositas.The cause of disease and
Pathogenesis not yet illustrates.Some patientss see mosquito, bedbug or other insects bite after fall ill, with gastrointestinal dysfunction and
Dysendocrinism may also have certain relationship.
This kind of disease mainly includes hormone, antihistamine, immunosuppressor, calming soporific class medicine interior use or outer in the treatment
With additionally can be using the drugs such as the closing of procaine hydrochloride vein, Thalidomide.Can also Applied Physics therapy such as freezing control
It treats, chemotherapy, phototherapy, photodynamic therapy and x-ray radiotherapy etc..But such disease often resists treatment, is easy to recurrence and adds
Weight.
Kushenin with having direct anti-inflammatory effect, immunoregulation effect, inhibiting tumor proliferation, make by induction differentiation and apoptosis
With, anti-virus sterilizing effect, anti anoxia, expands blood vessel, reducing blood lipid, anti-arrhythmia, calmness, antipyretic, cooling, improves hemorheology
Learn indices effect.For the etiology and pathogenesis of the diseases related morbidity of cutaneous lymphoid hyperplasia, in central nervous system, oxidation is bitter
Ginseng alkali has the function of calm, analgesia, antipyretic, cooling, can inhibit cause and itches after the factor stimulates, and nerve impulse reaches cerebral cortex,
Lead to itch；Oxymatrine, matrine are that have hormone-like effect and the strength anti-inflammatory agent without hormone side effect；With stronger
Immunoregulation effect can pass through the variation of antibody level, immunocyte to host, cell factor and other inflammatory mediators
Influence play its anti-inflammatory effect；Kushenin has anti-allergy action, can inhibit the generation of metamorphosis reaction.But kuh-seng
Effective extract or matrine in clinic, there are diuresis row side effects, the patients for causing urine volume excessive such as sodium to make for a long time
With.Glycyrrhizic acid has the effects that anti-inflammatory, antiallergic action, antiviral, liver protection, for the morbidity of neuropsychiatric disorders dermatoses
The steroids sample effect of etiology and pathogenesis, glycyrrhizic acid has the anti-inflammatory effect and antiallergic action of neuropsychiatric disorders dermatoses
Remarkable effect.But the steroids sample of glycyrrhizic acid acts on, the effective component extracts or glycyrrhizic acid of long-term a large amount of oral Radix Glycyrrhizaes and its
Derivative can make patient, and there are the serious adverse reactions such as water-sodium retention, hypertension and Diagnostic value.
The present invention is provided for neuropsychiatric disorders dermatoses by experiment with adduction synergistic effect and the secondary work of poison
With lower completely new pharmaceutical composition, and its preparation is for treating the application in neuropsychiatric disorders dermatoses.
Summary of the invention
This invention people is by experiment it has surprisingly been found that kushenin (oxymatrine, matrine) or derivatives thereof and sweet
The pharmaceutical composition of oxalic acid or derivatives thereof can provide particularly advantageous treatment neuropsychiatric disorders dermatoses effect, without
Observe apparent side effect.And this pharmaceutical composition particularly suitable for treatment neuropsychiatric disorders dermatoses (including
Pruritus, lichen simplex chronicus, pruigo, prurigo nodularis, pigmentosa pruigo and lichenoid dermatitis) treatment.This drug
The technology of existing treatment neuropsychiatric disorders dermatoses can also be combined such as: hormone, chemotherapy, is immunized and controls antihistamine
Treatment, biological response modifiers, physiotherapy, radiotherapy, phototherapy, photochemotherapy and optical dynamic therapy.
The object of the present invention is to provide a kind of pharmaceutical composition for treating neuropsychiatric disorders dermatoses, affiliated medicine groups
Close object include sequence give or give pharmaceutically acceptable amount simultaneously or medicine effective dose kushenin or derivatives thereof and
Glycyrrhizic acid or derivatives thereof, especially pharmaceutical acceptable form or its pharmaceutical salts.It further include glycyrrhizic acid matrine salt and glycyrrhizic acid
Kushenin salt.
The weight proportion of kushenin or derivatives thereof and glycyrrhizic acid or derivatives thereof is 10:1 ~ 1:10 in composition, preferably
Be 5:1 ~ 1:5, more preferable 5:1 ~ 1:2.Wherein kushenin or derivatives thereof content be 50 ~ 2000mg, further preferably 100
~ 1500mg, more preferably 300 ~ 1000mg；Glycyrrhizic acid or derivatives thereof content be 30 ~ 2000mg, further preferably 30 ~
1500mg, more preferably 100 ~ 1000mg.
It is administered simultaneously including giving kushenin or derivatives thereof and glycyrrhizic acid or derivatives thereof, or by every kind of activating agent
Independent preparation is substantially simultaneously administered.Sequence, which is given, to be referred to and in chronological sequence gives kushenin according to clinical treatment or it spreads out
Biology, glycyrrhizic acid or derivatives thereof.Kushenin that the present invention provides or derivatives thereof and glycyrrhizic acid or derivatives thereof drug scalar,
It is to be provided about compound itself, such as the kushenin of 100mg hydrochloride form refers to the hydrochloride containing 50mg kushenin
Amount.
In the present invention, active medicine is administered preferably in the form of pharmaceutical composition, and this composition may include a variety of medicines
Object or only a kind of drug.Described pharmaceutical composition can be by by kushenin of above-mentioned content range or derivatives thereof and glycyrrhizic acid
Or derivatives thereof after appropriate pharmaceutically acceptable form is mixed with acceptable carrier, according to the preparation of the pharmaceutical preparation of routine
It is prepared by method.
Kushenin or derivatives thereof and glycyrrhizic acid or derivatives thereof are (including medicines in the form of pharmaceutical acceptable respectively
Acceptable salt, ester and solvate on) as pharmaceutically active agents administration.Kushenin of the invention or derivatives thereof includes
Kushenin, oxymatrine, matrine, Iosmatrine or its officinal salt (including hydrochloride, sulfate, acetate, phosphoric acid
Salt, fumarate and various amino-acid salts).Glycyrrhizic acid or derivatives thereof includes glycyrrhizic acid, glycyrrhizin, Isoglycyrrhiza acid, different
Glycyrrhetate, glycyrrhetate etc., glycyrrhetate include that glycyrrhizin can medication salt, ammonium glycyrrhizinate, diammonium glycyrrhizinate, glycyrrhizic acid
Glycosides, sodium glycyrrhetate, potassium glycyrrhizana and Radix Glycyrrhizae acid calcium salt etc..It further include glycyrrhizic acid matrine salt and glycyrrhizic acid kushenin salt.
By the quality proportioning and corresponding auxiliary material can be added in described pharmaceutical composition, be made and be suitble to oral administration, note
Penetrate the dosage form of administration, percutaneous dosing, transmucosal absorption administration or other dosage forms.Described pharmaceutical composition can be prepared into greatly
Or the dosage forms such as the injection of low capacity, freeze-dried powder, aseptic powder packing, it is also possible to tablet, capsule, pulvis, dripping pill, micro-
Ball, particle, pastille, suppository, oral solution or sterile parenteral solutions or suspension formulation form or other dosage forms such as emulsion, paste
Deng.Oral liquid can be the forms such as emulsion, syrup, can also be used as dry products presence, using it is preceding again with water or its
He reconstitutes suitable carrier.Auxiliary material includes (being not limited to) physiologically acceptable pharmaceutical excipient and pharmaceutic adjuvant.Wherein
Pharmaceutic adjuvant includes one or more of sodium chloride, mannitol, PVP K30, glucose, lactose and combinations thereof.
In order to reach the consistency of administration, the present composition is preferably unit dose form.
For oral administration, containing pharmaceutically conventional excipient such as adhesive, for example (,) it is syrup, Arabic gum, bright
Glue, sorbierite, tragacanth, polyvinylpyrrolidone, hydroxypropyl methylcellulose, dextrin, polyethylene glycol etc.；Filler, such as lactose,
Sugar, cornstarch, calcium phosphate, sorbierite, glycine etc.；Tableting lubricant, such as magnesium stearate, polyethylene glycol etc.；Disintegrating agent,
Such as starch, polyvinylpyrrolidone, Explotab or microcrystalline cellulose；Pharmaceutically acceptable wetting agent, such as 12
Sodium alkyl sulfate etc.；Suspending agent, such as sorbierite, syrup, methylcellulose, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose
Element, aluminum stearate gel or the edible ester of hydrogenation etc.；Emulsifier, such as lecithin, anhydro sorbitol-oleate, Arabic gum
Deng；Anhydrous carrier (may include edible oil), such as apricot kernel oil, evaporating coconut oil or oily ester；Preservative, such as para hydroxybenzene
Methyl formate, propyl ester, sorbic acid etc.；Corrigent and sweetener, such as rebaudioside, Aspartame, Steviosin, xylitol, peppermint
Alcohol, flavoring orange essence etc.；Colorant etc. can also be added.Preparation method uses the preparation method of this field routine.
For parenteral, especially injection, unit is prepared respectively at sterile carrier using two kinds of active components
Liquid dosage form, and be suspended or dissolved in carrier according to concentration used.It, can be molten by active constituent when preparing liquid
Solution is filled into container is sealed later in water for injection and filtration sterilization.Advantageously, in order to be suitble to intravenous injection can be with
The common adjuvant of injection such as preservative, buffer, acidity-basicity regulator, Osmolyte regulator, solubilizer, stabilization is added
Agent, antioxidant etc..
In addition can also conventionally by pharmaceutical composition single active ingredient or pharmaceutical composition slow control is made
Release formulation, such as sustained release pellet or controlled release micro pill.
Preferably unit dose is made with the amount with relevant date appropriate dosage in described pharmaceutical composition.It can be with daily administration 1 ~ 6
It is secondary, but most preferably it is administered once daily (drug administration by injection) or 3 times (oral administration and topical administration).
According to administration mode and the difference of formulation requirements, in the composition kushenin or derivatives thereof and glycyrrhizic acid or its spread out
The sum of biological content can be the 0.1% ~ 99% of total amount, preferably 1% ~ 60%.
The present invention is by the way that experimental results demonstrate the pharmaceutical compositions of kushenin or derivatives thereof and glycyrrhizic acid or derivatives thereof
Treating neuropsychiatric disorders dermatoses has especially significant effect, and toxic side effect is lower.
Specific embodiment
We illustrate the present invention in conjunction with the embodiments below.Following embodiment is merely to illustrate technical side of the invention
Case is not intended to limit the present invention.
Embodiment 1
The comparison that oxymatrine, glycyrrhizic acid and combinations thereof act on Mouse Acute Toxicity
Kunming mice is randomly divided into Normal group and test medicine group, and every group ten, half male and half female.Except Normal group
Outside, test medicine group be injected intraperitoneally respectively (ip) large dosage of oxymatrine, glycyrrhizin and two kinds of components composition it is primary,
It is observed continuously 7 days, records death time and the death toll of animal.
The results show that there is larger toxicity when the dosage of oxymatrine is 950mg/kg, 9 death in 10 mouse,
When glycyrrhizin dosage is 950mg/kg, 2 death in 10 mouse, and Oxymatrine subtracts: glycyrrhizin is 1:1 and shares agent
Amount is 950mg/kg and kushenin: glycyrrhizin is 2:1 and shares dosage when being 950mg/kg, no animal dead, Oxymatrine
Subtract: glycyrrhizin is 3:1 and shares dosage when being 950mg/kg, 2 animal deads, illustrate oxymatrine and glycyrrhizin into
Row proportion combination, toxicity is substantially reduced, and oxymatrine, glycyrrhizin match its toxicity by 1:1 and 2:1 and match less than 3:1
Than.
The comparison that 1 oxymatrine of table, glycyrrhizic acid and combinations thereof (ip is primary) acts on Mouse Acute Toxicity
| Group | Dosage (mg/kg) | Death toll/sum |
| Normal group | 0 | 0/10 |
| It is bitter | 950 | 9/10 |
| It is sweet | 950 | 2/10 |
| Bitter+sweet (1:1) | 950 | 0/10 |
| Bitter+sweet (2:1) | 950 | 0/10 |
| Bitter+sweet (3:1) | 950 | 2/10 |
Remarks: " hardship ": oxymatrine is indicated；" sweet ": glycyrrhizin is indicated
Embodiment 2
The observation of curative effect of compound glycyrrhizin co-oxidation Sophorcarpidine Treating lichen simplex chronicus
1 data and method
1.1 clinical data clinical diagnosises meet 40 patients of general hair property lichen simplex chronicus, and male 20, female 20
Example the age 23 ~ 55 years old, did not received treatment, the serious viscera disease such as no liver and kidney dysfunction, no active lung knot in January
Core, high blood pressure, diabetes, cataract medical history reject the gestational period, breast feeding women.Patient is randomly divided into four groups: oxidation is bitter
Can Jian treatment group (A group), SNMC in Treatment group (B group), oxymatrine combine SNMC in Treatment group (C
Group), control group (D group), every group ten, men and women is fifty-fifty.Four groups poor without statistics on age, gender, coincident with severity degree of condition
Different (P ﹥ 0.05).
1.2 treatment method A group intravenous drip Oxymatrine Injection 0.6g100ml/d；B group intravenous drip compound is sweet
Oxalic acid glycoside injection liquid 120mg/d；C group gives intravenous drip Oxymatrine Injection 0.6g100ml/d, compound glycyrrhizin note
Penetrate liquid 120mg/d；It is oral that control group awards levocetirizine capsule 5mg；Four groups cooperate Triamcinolone acetonide benefit chaff azoles emulsifiable paste simultaneously
External application, it is as a treatment course with 4 weeks, after the course for the treatment of after carry out efficacy determination.To trouble after the first visit same day and treatment four weeks
Person's sings and symptoms are observed (including itch, erythema, papule, exudation, erosion, infiltration or mossization, angling furfur etc.), respectively
Index is pressed 4 grades of point systems in each assessment and is carried out: 0=nothing, 1=slight, 2=moderate, 3=severe.Scoring is made, evaluation is treated
Effect, and observe side effect.
1.3 the standard of curative effect evaluation: integrated value calculation formula are as follows: integrated value=(integrate the product after total ﹣ is treated 2 weeks first visit day
Subtotaling)/first visit day integrate total × 100%.Cure: integrated value reduces > 95%；Effective: integrated value reduces 61% ~ 95%；It is good
Turn: integrated value reduces 20 ~ 60%；Integrated value reduces < 20%.
1.4 two groups of safety evaluatios (are wrapped with blood urine routine, biochemical routine is checked before treatment, after each course for the treatment of
Include hepatic and renal function, blood glucose, electrolyte and blood lipid), and the adverse reaction occurred during treatment is recorded, serious adverse reaction occurs and moves back
Observer is judged in vain out.
2 results
2 four groups of curative effect comparative examples (%) of table
A group=Oxymatrine Treating group；B group=SNMC in Treatment group；C group=oxymatrine joint compound is sweet
Oxalic acid glycosides treatment group；D group=control group.
3. 2 readme urine volume of adverse reaction A group increase, 1 times of defecation by increasing to 2 times a day once a day；B group 3
There is out of strength, slight abdominal distension in example, and 1 hypopotassaemia occurs, and 2 Mild edema symptom occur；C group and D group do not occur bad
Reaction；A, it does not influence to treat for two groups of B.Pretherapy and post-treatment four groups of blood urines are routinely showed no apparent exception.
3. conclusion
Oxymatrine combines SNMC in Treatment lichen simplex chronicus significant effect, and effective percentage is up to 100%, not
Adverse reaction occurs.
Embodiment 3
The clinical observation of compound glycyrrhizin co-oxidation Sophorcarpidine Treating prurigo nodularis
1 data and method
1.1 clinical data clinical diagnosises meet 40 patients of prurigo nodularis, 20 male, and female 20, the age 35 ~ 51
In year, do not received treatment in January, the serious viscera disease such as no liver and kidney dysfunction, no active pulmonary tuberculosis, high blood pressure,
Diabetes, cataract medical history reject the gestational period, breast feeding women.Patient is randomly divided into four groups: Oxymatrine Treating group (A
Group), SNMC in Treatment group (B group), oxymatrine combine SNMC in Treatment group (C group), control group (D
Group), every group ten, men and women is fifty-fifty.Four groups of equal no difference of science of statistics (P ﹥ 0.05) on age, gender, coincident with severity degree of condition.
1.2 treatment method A group intravenous drip Oxymatrine Injection 0.6g100ml/d；B group intravenous drip compound is sweet
Oxalic acid glycoside injection liquid 120mg/d；C group gives intravenous drip Oxymatrine Injection 0.6g100ml/d, compound glycyrrhizin note
Penetrate liquid 120mg/d；It is oral that control group awards levocetirizine capsule 5mg；Four groups cooperate Triamcinolone acetonide benefit chaff azoles emulsifiable paste simultaneously
External application, it is as a treatment course with 4 weeks, after the course for the treatment of after carry out efficacy determination.To trouble after the first visit same day and treatment four weeks
Person's sings and symptoms are observed (including itch, erythema, papule, exudation, erosion, infiltration or mossization, angling furfur etc.), respectively
Index is pressed 4 grades of point systems in each assessment and is carried out: 0=nothing, 1=slight, 2=moderate, 3=severe.Scoring is made, evaluation is treated
Effect, and observe side effect.
1.3 the standard of curative effect evaluation: integrated value calculation formula are as follows: integrated value=(integrate the product after total ﹣ is treated 2 weeks first visit day
Subtotaling)/first visit day integrate total × 100%.Cure: integrated value reduces > 95%；Effective: integrated value reduces 61% ~ 95%；It is good
Turn: integrated value reduces 20 ~ 60%；Integrated value reduces < 20%.
1.4 two groups of safety evaluatios (are wrapped with blood urine routine, biochemical routine is checked before treatment, after each course for the treatment of
Include hepatic and renal function, blood glucose, electrolyte and blood lipid), and the adverse reaction occurred during treatment is recorded, serious adverse reaction occurs and moves back
Observer is judged in vain out.
2 results
2 four groups of curative effect comparative examples (%) of table
A group=Oxymatrine Treating group；B group=SNMC in Treatment group；C group=oxymatrine joint compound is sweet
Oxalic acid glycosides treatment group；D group=control group.
3. 3 readme urine volume of adverse reaction A group increase；3 appearance of B group are out of strength, and slight abdominal distension, 1 hypokalemia occurs
Disease, 2 there is Mild edema symptom；C group and D group do not occur adverse reaction；A, it does not influence to treat for two groups of B.Before and after treatment
Four groups of blood urines are routinely showed no apparent exception.
3. conclusion
Oxymatrine combines SNMC in Treatment lichen simplex chronicus significant effect, and effective percentage is up to 100%, not
Adverse reaction occurs.
Embodiment 4
Oxymatrine 200mg
Diammonium glycyrrhizinate 150mg
NaCl 0.9g
Appropriate water for injection
Every 100ml
NaCl is taken, with water for injection stirring and dissolving, oxymatrine, diammonium glycyrrhizinate is then respectively adding, continues to stir
When be completely dissolved, add and inject water to total amount, filtration to clear and bright, potting, sterilizing to get.
Embodiment 5
Oxymatrine 200g
Glycyrrhizin 150g
Sodium Hydroxymethyl Stalcs 10g
Lactose 50g
Magnesium stearate 0.5g
Appropriate pure water
It is made 1000
It by oxymatrine, glycyrrhizin, in advance crushed 80 meshes, lactose taken to cross 80 meshes, it is spare.Take the upper of sieving
It states fine powder to weigh by above-mentioned prescription, is uniformly mixed, mixed powder is put into mixing machine, pure water is added while stirring, stir
Softwood, granulation, 50 ~ 60 DEG C of dryings of wet grain is made within 15 minutes, whole grain is added Sodium Hydroxymethyl Stalcs, magnesium stearate, mixes, tabletting,
To obtain the final product.
Embodiment 6
Oxymatrine 200mg
Diammonium glycyrrhizinate 150mg
Microcrystalline cellulose 27.5mg
Lactose fruit-appropriate hydrate
Magnesium stearate 0.5mg
Film-making
After mixing by above-mentioned raw materials, auxiliary material, it pelletizes according to conventional wet lay, dry, tabletting.
Embodiment 7
Oxymatrine 200mg
Diammonium glycyrrhizinate 150mg
Microcrystalline cellulose 27.5mg
Lactose fruit-appropriate hydrate
Magnesium stearate 0.5mg
Film-making
After mixing by above-mentioned raw materials, auxiliary material, it pelletizes according to conventional wet lay, dry, tabletting.
Embodiment 8,18 β-glycyrrhizic acid matrine salt
18 β-glycyrrhizic acid 165g and matrine 49.7g is taken to be added in appropriate anhydrous methanol, stirring and dissolving, continues to stir at room temperature
It is slowly added to after mixing several minutes in the 3000ml acetone being vigorously stirred, washes out a large amount of white crystalline powders, filtered, it is true in 60 DEG C
Sky is dry, obtains white crystalline powder 172g, yield 80.1%.
Mp:204 DEG C of decomposition
[C]D 20=+24.5 (1% ethyl alcohol)
| Elemental analysis | Measured value (%) | Calculated value (%) |
| C | 63.88 | 63.91 |
| H | 8.12 | 8.09 |
| N | 2.70 | 2.61 |
Embodiment 9,18 β-glycyrrhizic acid kushenin salt
18 β-glycyrrhizic acid 165g and kushenin 106g is taken to be added in appropriate anhydrous methanol, stirring and dissolving, continues to stir at room temperature
It is slowly added to after mixing several minutes in the 3000ml acetone being vigorously stirred, washes out a large amount of white crystalline powders, filtered, it is true in 60 DEG C
Sky is dry, obtains white crystalline powder 188g, yield 69.4%.
Mp:206 DEG C of decomposition
[C]D 20=+42.4 (1% ethyl alcohol)
| Elemental analysis | Measured value (%) | Calculated value (%) |
| C | 63.91 | 63.98 |
| H | 8.31 | 8.20 |
| N | 4.12 | 4.15 |
Embodiment 10,18 alpha-liquorice acid matrine salts
18 alpha-liquorice acid 165g and matrine 49.7g are taken to be added in appropriate anhydrous methanol, stirring and dissolving, continues to stir at room temperature
It is slowly added to after mixing several minutes in the 3000ml acetone being vigorously stirred, washes out a large amount of white crystalline powders, filtered, it is true in 60 DEG C
Sky is dry, obtains white crystalline powder 180g, yield 83.8%.
Mp:208 DEG C of decomposition
[C]D 20=+23.6 (1% ethyl alcohol)
| Elemental analysis | Measured value (%) | Calculated value (%) |
| C | 63.88 | 63.91 |
| H | 8.10 | 8.09 |
| N | 2.59 | 2.61 |
Embodiment 11,18 alpha-liquorice acid kushenin salt
18 alpha-liquorice acid 165g and matrine 106g are taken to be added in appropriate anhydrous methanol, stirring and dissolving, continues to stir at room temperature
It is slowly added to after mixing several minutes in the 3000ml acetone being vigorously stirred, a large amount of white crystalline powders is precipitated, filtered, it is true in 60 DEG C
Sky is dry, obtains white crystalline powder 190g, yield 73.1%.
Mp:210 DEG C of decomposition
[C]D 20=+24.2 (1% ethyl alcohol)
| Elemental analysis | Measured value (%) | Calculated value (%) |
| C | 63.79 | 63.98 |
| H | 8.31 | 8.20 |
| N | 4.19 | 4.15 |
Embodiment 12: the freeze-dried powder preparation of the double kushenin compound salts of glycyrrhizic acid
In 100ml reaction flask, glycyrrhizic acid 2.00g(2.43mmol is added), a water kushenin 1.372g (4.86mmol),
Deionized water 30ml is added, stirring and dissolving filters, and filtrate freeze-drying obtains freeze-dried powder 3.26g, yield 99.3%.
Embodiment 13: the freeze-dried powder preparation of three kushenin compound salt of glycyrrhizic acid
In 100ml reaction flask, glycyrrhizic acid 2.00g(2.43mmol is added), a water kushenin 2.06g (7.29mmol),
Deionized water 30ml is added, stirring and dissolving filters, and filtrate freeze-drying obtains freeze-dried powder 3.88g, yield 98.8%.
Embodiment 14: the preparation of the complex salt of glycyrrhizic acid and kushenin
In 100ml reaction flask, deionized water 40ml is added, at normal temperature, glycyrrhizic acid 2.00g(2.43mmol is added),
One water kushenin 0.686g (2.43mmol), stirring and dissolving, 60 DEG C of water-bath are rushed pump decompression (20mmHg) with water and are concentrated into 10ml, are stirred
It mixes down and acetone is slowly added dropwise, so that the white oil turbidity sediment dissolution being precipitated, when acetone is added dropwise to 20ml, the white of precipitation
Oily turbidity sediment is not redissolved, and acetone is added dropwise in pause, and stirring to white oil precipitating is converted into white crystalline solid, about needs 30
Minute to 1 hour, continue to be added dropwise acetone in 30 minutes to 60ml, in 50 DEG C stirred in water bath 1 hour, then naturally cool to
It is stirred at room temperature 2 hours, filters, acetone washing, be dried in vacuo in 50 DEG C, obtain white crystals 2.2g, m.p:202-204 DEG C, yield
It is 83.3%.
Table elemental analysis result (C42H62O16.C15H24N2O2)
| C weight content | H weight content | N weight content | |
| Calculated value | 62.96% | 7.97% | 2.57% |
| Experiment value | 62.43% | 7.88% | 2.48% |
Embodiment 15: the powder-injection preparation of the complex salt of glycyrrhizic acid and kushenin
In sterile weighing area, 4g mannitol is claimed to be added in appropriate container, add 800ml water for injection, stirring is allowed to abundant
Dissolution is added the complex salt stirring and dissolving of 50g glycyrrhizic acid and kushenin, injects water to 1000ml, aseptically, uses
Dispensed after 0.22 μm of filtering with microporous membrane, loading amount be every bottle of 10ml, freeze-drying, add sterilizing fill in and roll outer cover to get.
Embodiment 16: the preparation of the freeze-dried powder of composition
Oxymatrine and glycyrrhizin composition (1 ~ 10:1 ~ 10), matrine and glycyrrhizin composition (1 ~ 10:1 ~
10), oxymatrine and Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~ 10), matrine and Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~
10), the double kushenin compound salts of glycyrrhizic acid kushenin compound salt, glycyrrhizic acid, three kushenin compound salt of glycyrrhizic acid, 18 alpha-liquorice acids are bitter
Join plain salt, 18 alpha-liquorice acid matrine salts, 18 β-glycyrrhizic acid matrine salt, 18 β-glycyrrhizic acid kushenin salt,
At normal temperatures and pressures, one of mentioned component is added in reagent bottle, is added well-known in the art suitable
Deionized water stirring, is after completely dissolution concentrated under reduced pressure dissolution system；Secondly, instilling water-soluble solvent under agitation, analyse
White precipitate out；Finally, be stirred under 50 DEG C of water bath conditions makes transformation of crystal and stirs under room temperature to make crystallization respectively
It completes, is filtered later, wash, the white crystals of one of mentioned component are made in the operating procedures such as 50 DEG C of vacuum drying；Or
It is freeze-dried by aqueous solution obtained above and freeze-dried powder is made.
Embodiment 17: the injection preparation of composition
Oxymatrine and glycyrrhizin composition (1 ~ 10:1 ~ 10), matrine and glycyrrhizin composition (1 ~ 10:1 ~
10), oxymatrine and Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~ 10), matrine and Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~
10), the double kushenin compound salts of glycyrrhizic acid kushenin compound salt, glycyrrhizic acid, three kushenin compound salt of glycyrrhizic acid, 18 alpha-liquorice acids are bitter
Join plain salt, 18 alpha-liquorice acid matrine salts, 18 β-glycyrrhizic acid matrine salt, 18 β-glycyrrhizic acid kushenin salt
One of mentioned component 50g is added in appropriate containers, the water for injection of addition total volume about 85%, stirring and dissolving,
PH value is surveyed, adjusts pH value about 6.0 ~ 6.5 with hydrochloric acid solution or sodium hydroxide solution, 900g is added, stirring is allowed to dissolve, and filling is penetrated
With water to 10L, stirring make uniformly after with 0.22 μm of filtering with microporous membrane, rush nitrogen, encapsulating, 115 DEG C pressure sterilizing 30 minutes, lamp
Inspection is examined, packaging.
Embodiment 18:
Oxymatrine 600mg
Diammonium Glycyrrhizinate 150mg
NaCl 0.9g
Appropriate water for injection
Sodium chloride water for injection stirring and dissolving is taken, oxymatrine, Diammonium Glycyrrhizinate are then respectively adding, continues to stir
To be completely dissolved day to inject water to total amount, filtration to clear and bright, encapsulating, sterilizing to get.
Embodiment 19: the tablet preparation of composition
Oxymatrine and glycyrrhizin composition (1 ~ 10:1 ~ 10), matrine and glycyrrhizin composition (1 ~ 10:1 ~
10), oxymatrine and Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~ 10), matrine and Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~
10), the double kushenin compound salts of glycyrrhizic acid kushenin compound salt, glycyrrhizic acid, three kushenin compound salt of glycyrrhizic acid, 18 alpha-liquorice acids are bitter
Join plain salt, 18 alpha-liquorice acid matrine salts, 18 β-glycyrrhizic acid matrine salt, 18 β-glycyrrhizic acid kushenin salt
One of mentioned component 50g
Pregelatinized starch 2g
Hydroxypropyl cellulose 4g
Sodium carboxymethyl starch 3.5g
Microcrystalline cellulose 1g
Magnesium stearate 0.4g
One of mentioned component and above-mentioned each auxiliary material are crossed into 80 meshes respectively, is uniformly mixed, has povidone that softwood is made, with 14
The granulation of mesh nylon mesh, 50 ~ 60 DEG C of dryings, 14 mesh sieves carry out tabletting after mixing and are made.
Embodiment 20: the granule preparation of composition
Oxymatrine and glycyrrhizin composition (1 ~ 10:1 ~ 10), matrine and glycyrrhizin composition (1 ~ 10:1 ~
10), oxymatrine and Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~ 10), matrine and Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~
10), the double kushenin compound salts of glycyrrhizic acid kushenin compound salt, glycyrrhizic acid, three kushenin compound salt of glycyrrhizic acid, 18 alpha-liquorice acids are bitter
Join plain salt, 18 alpha-liquorice acid matrine salts, 18 β-glycyrrhizic acid matrine salt, 18 β-glycyrrhizic acid kushenin salt
One of mentioned component 50g
Honey element 8g
Lactose 8g
Appropriate essence
One of mentioned component is dissolved in water, starch 80g, Icing Sugar 20g is added, then flavoring essence is in right amount, mixes, with 14 ~ 16 mesh
Sieve granulation, 60 DEG C or less dryings, packaging.
Embodiment 21: the capsule preparation of composition
Oxymatrine and glycyrrhizin composition (1 ~ 10:1 ~ 10), matrine and glycyrrhizin composition (1 ~ 10:1 ~
10), oxymatrine and the double kushenins of Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~ 10), glycyrrhizic acid kushenin compound salt, glycyrrhizic acid
Complex salt, three kushenin compound salt of glycyrrhizic acid, 18 alpha-liquorice acid kushenin salt, 18 alpha-liquorice acid matrine salts, 18 β-glycyrrhizic acid
Matrine salt, 18 β-glycyrrhizic acid kushenin salt
One of mentioned component 50g
Starch 5g
Microcrystalline cellulose 2g
Magnesium stearate 1g
One of mentioned component and above-mentioned each auxiliary material are sieved respectively, and are uniformly mixed, be sub-packed in hard capsule to get.
Embodiment 22: the oral solution preparation of composition
Oxymatrine and glycyrrhizin composition (1 ~ 10:1 ~ 10), matrine and glycyrrhizin composition (1 ~ 10:1 ~
10), oxymatrine and Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~ 10), matrine and Diammonium Glycyrrhizinate composition (1 ~ 10:1 ~
10), the double kushenin compound salts of glycyrrhizic acid kushenin compound salt, glycyrrhizic acid, three kushenin compound salt of glycyrrhizic acid, 18 alpha-liquorice acids are bitter
Join plain salt, 18 alpha-liquorice acid matrine salts, 18 β-glycyrrhizic acid matrine salt, 18 β-glycyrrhizic acid kushenin salt
One of mentioned component 50g
Propylene glycol 5g
Glycerol 1g
Gelatin 2g
Sucrose 10g
Sodium benzoate 0.1g
Citric acid 0.5g
Appropriate essence
Pure water 100g
After pure water is added with above-mentioned each auxiliary material in one of mentioned component, stirring and dissolving is dispensed to obtain the final product.
Embodiment 23: the sustained release pellet preparation of composition
Slow-released part prescription (ball 1)
Capsule core prescription
Kushenin 200g
Glycyrrhizin 150g
Microcrystalline cellulose 15g
Hydroxypropyl methylcellulose 5g
Pure water 200ml
It is made 1000
It is coated prescription
25% aqueous ethylcellulose dispersion liquid 184g
Pure water 123g
It is made 1000
Respectively microcrystalline cellulose, kushenin, glycyrrhizin be crushed into 80 meshes in advance, weighed by 1 prescription of ball, mixing is equal
Even, hypromellose aqueous solution makees adhesive, and pellet processed, by it in 50 ~ 60 DEG C of dryings, the piller of 20 ~ 30 mesh is spare.
The pellet that will be prepared and choose, sets in fluidized bed, sprays mode the bottom of using, passes through hot-air suspension fluidization, air inlet temperature
Degree is 55 DEG C, and at 30 DEG C, adjusting peristaltic pump makes it provide coating solution, mist by the speed of 5g slurries per minute for material bed tempertaure control
Change pressure 2bar, start continuously to whitewash to the piller of fluidisation, after whitewashing, reduce air quantity, make pellet under slight boiling condition in
40 DEG C of dry a moments.Taking-up is placed in 40 DEG C of baking ovens 24 hours dry, weight gain about 18%, measure content to get.
Claims (6)
1. a kind of composition is in preparation for treating the purposes in neuropsychiatric disorders dermatoses pharmaceutical composition, feature exists
In the composition is grouped as by following two kinds of groups: first group of kushenin for being divided into pharmaceutically acceptable form or its is pharmaceutically acceptable
Salt, second group is divided into glycyrrhizic acid or its officinal salt, and the weight proportion of first component and second component is 5:1,
The composition dosage form is injection.
2. purposes according to claim 1, which is characterized in that the content of first component is 50 ~ 2000mg, described the
The content of two components is 30 ~ 2000mg.
3. purposes according to claim 1, which is characterized in that the content of first component is 100 ~ 1500mg, described
The content of second component is 30 ~ 1500mg.
4. purposes according to claim 1, which is characterized in that the content of first component is 300 ~ 1000mg, described
The content of second component is 100 ~ 1000mg.
5. described in any item purposes according to claim 1 ~ 4, which is characterized in that the form of the pharmaceutical composition substance is
Powder-injection.
6. purposes according to claim 1-4, which is characterized in that the neuropsychiatric disorders dermatoses packet
Include pruritus, lichen simplex chronicus, pruigo, prurigo nodularis, pigmentosa pruigo and lichenoid dermatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410343670.3A CN105267228B (en) | 2014-07-18 | 2014-07-18 | A kind of pharmaceutical composition is as the application in preparation treatment neuropsychiatric disorders dermatoses drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410343670.3A CN105267228B (en) | 2014-07-18 | 2014-07-18 | A kind of pharmaceutical composition is as the application in preparation treatment neuropsychiatric disorders dermatoses drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105267228A CN105267228A (en) | 2016-01-27 |
| CN105267228B true CN105267228B (en) | 2019-02-26 |
Family
ID=55137629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410343670.3A Active CN105267228B (en) | 2014-07-18 | 2014-07-18 | A kind of pharmaceutical composition is as the application in preparation treatment neuropsychiatric disorders dermatoses drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105267228B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695624A (en) * | 2004-05-12 | 2005-11-16 | 江苏恒瑞医药股份有限公司 | Combination of medication of containing kurarinone and glycyrrhetic acid, and application |
-
2014
- 2014-07-18 CN CN201410343670.3A patent/CN105267228B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695624A (en) * | 2004-05-12 | 2005-11-16 | 江苏恒瑞医药股份有限公司 | Combination of medication of containing kurarinone and glycyrrhetic acid, and application |
Non-Patent Citations (2)
| Title |
|---|
| 《甘草及其有效成分的皮肤药理和临床应用》;张明发等;《药物评价研究》;20130430;第36卷(第2期);第146-156页 |
| 《苦参素联合普鲁卡因治疗全身性皮肤瘙痒疗效观察》;吴友良等;《西南国防医药》;20050131;第15卷(第1期);第53-54页 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105267228A (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN109381471B (en) | Combination product comprising limonoids and biguanides | |
| KR20160117426A (en) | Desmodium styracifolium (osb.) merr. flavonoids capsule, method of preparing same, and application thereof | |
| CN101708241B (en) | Medicinal composition for eliminating dampness and relieving itching | |
| ES2555927T3 (en) | Compositions of modified release of epalrestat or a derivative thereof and methods for using them | |
| WO2016008650A1 (en) | Combination of valerian root extract and lavender oil for use in the treatment of sleep disorders | |
| WO2020039264A2 (en) | Chemotherapeutic pharmaceutical suspension for oral dosage | |
| EP4014999B1 (en) | Combination product containing limonin compound and sulfonylurea drug | |
| CN110279866B (en) | Combination product comprising limonoids and thiazolidinediones | |
| CN104138376A (en) | A sustained release agent improving anoxia endurance | |
| CN104161763B (en) | A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema | |
| CN105311044B (en) | A kind of pharmaceutical composition is as the application in preparation treatment cutaneous vasculitis drug | |
| CN105267228B (en) | A kind of pharmaceutical composition is as the application in preparation treatment neuropsychiatric disorders dermatoses drug | |
| CN110327356A (en) | Combination product comprising limonoid and alpha-glucosidase inhibitor | |
| CN102716135A (en) | Application of lupenone to products for preventing or treating diabetes mellitus | |
| CN105311024B (en) | Kushenin and its derivative are as the application prepared in treatment cutaneous vasculitis drug | |
| CN105267227B (en) | A kind of pharmaceutical composition is as the application in preparation treatment sterile pustular skin disease drug | |
| CN105311043B (en) | The application for preparing in drug of the composition in the preparation treatment dermotosis of metabolism disturbance | |
| CN103596573B (en) | The method of process hypercortisolism, headache imbalance, neuropathic pain and related disorder | |
| CN105311025B (en) | Kushenin and its derivative are as the application prepared in treatment sterile pustular skin disease drug | |
| CN105311023B (en) | The pharmacy application of oxymatrine | |
| CN105287538B (en) | Kushenin and its derivative are as the application in preparation treatment lichen planus drug | |
| CN105944104B (en) | A kind of pharmaceutical composition for treating digestive tract ulcer | |
| CN104161764B (en) | The application for the treatment of psoriasis is prepared containing the pharmaceutical composition of kushenin and glycyrrhizic acid | |
| CN104605344A (en) | Health food for enhancing immunity and preparation method of health food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |